Stocktoria
Sotera Health Co SHC
Sotera Health Co (SHC) earns a Piotroski F-score of 6/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $1.2B at a 6.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-24 | Barclays | Overweight (main) |
| 2026-06-05 | Goldman Sachs | Buy (init) |
| 2026-05-06 | Piper Sandler | Overweight (reit) |
| 2026-04-14 | Barclays | Overweight (main) |
| 2026-02-24 | Citigroup | Buy (main) |
| 2026-01-09 | Piper Sandler | Overweight (up) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SHC | Sotera Health Co | 6/9 | — | 63.6 | +5.7% |
| PGNY | Progyny, Inc. | 5/9 | 7.14 | 38.2 | +10.4% |
| VMD | VIEMED HEALTHCARE, INC. | 5/9 | 5.41 | 26.5 | +20.5% |
| CCEL | CRYO CELL INTERNATIONAL INC | 5/9 | -3.07 | — | -1.3% |
| NIVF | NewGenIvf Group Ltd | 3/9 | 3.84 | 0.6 | — |
| MGRX | MANGOCEUTICALS, INC. | 2/9 | 2.42 | — | — |
| BRTX | BioRestorative Therapies, Inc. | 3/9 | — | — | — |
About Sotera Health Co
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
FAQ
Is SHC financially healthy?
Sotera Health Co's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak).
Does SHC pay a dividend?
No, Sotera Health Co does not currently pay a dividend.
How profitable is SHC?
In FY2025, Sotera Health Co had a net margin of 6.7% and a return on equity of 12.9%.
Is SHC overvalued or undervalued?
Sotera Health Co trades at about 70.0× trailing earnings — below its 10-year norm (10-year range 52.5×–85.7×, median 81.8×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for SHC?
The average Wall-Street price target for Sotera Health Co is $20.22, about 7.1% above the recent price, from 9 analysts (consensus: buy).
Is SHC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Sotera Health Co: a Piotroski F-score of 6/9, a P/E of about 63.6×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.